- [Resource Hub](/) - [Publication](/?resource-type=publication#library) - Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma # Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma Long GV, Shklovskaya E, Satgunaseelan L, Mao Y, da Silva IP, Perry KA, et al. Nature Medicine . 2025;31(5):1557-1566. DOI [10.1038/s41591-025-03512-1](https://doi.org/10.1038/s41591-025-03512-1). PMID 40016450. PMCID PMC12092302. How to cite ### AMA Long GV, Shklovskaya E, Satgunaseelan L, Mao Y, da Silva IP, Perry KA, et al. Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma. Nat Med . 2025;31(5):1557-1566. doi:10.1038/s41591-025-03512-1 ### APA Long, G. V., Shklovskaya, E., Satgunaseelan, L., Mao, Y., da Silva, I. P., Perry, K. A., et al. (2025). Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma. Nature Medicine , 31(5), 1557-1566. https://doi.org/10.1038/s41591-025-03512-1 ### BibTeX @article{long2025neoadjuvant, title = {Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma}, author = {Long, Georgina V. and Shklovskaya, Elena and Satgunaseelan, Laveniya and Mao, Yizhe and da Silva, Inês Pires and Perry, Kristen A. and others}, journal = {Nature Medicine}, volume = {31}, number = {5}, pages = {1557--1566}, year = {2025}, doi = {10.1038/s41591-025-03512-1}, pmid = {40016450} } Glioblastoma is an aggressive brain tumor that almost always returns within two years, and the immune checkpoint drugs that reshaped other cancers have shown little benefit when given after the tumor is removed. This report follows one newly diagnosed patient given a single dose of three checkpoint inhibitors together, before surgery rather than after, to test whether treating the tumor while still in place could provoke a stronger immune response. When the tumor was resected twelve days later, it carried heavy immune-cell infiltration, and circulating tumor cells in the blood fell to zero over the following months. Seventeen months on, there was no definitive sign the cancer had come back. The authors offer the case as the rationale for a planned first-line trial, not as proof that the approach works. [Read publication at Nature Medicine](https://pmc.ncbi.nlm.nih.gov/articles/PMC12092302/) ## Key findings - A single dose of neoadjuvant triplet checkpoint blockade preceded marked tumor-infiltrating-lymphocyte infiltration and activation. One dose of nivolumab (480 mg), relatlimab (160 mg) and ipilimumab (80 mg) was given on day +1, and the tumor resected 12 days later showed the anti-PD-1 agent bound to tumor-infiltrating lymphocytes with marked infiltration and activation over the day −4 baseline biopsy. - Circulating tumor cells zero-converted over the course of treatment. Using the AccuCyte–CyteFinder workflow, 16 glioblastoma circulating tumor cells were counted in 7.5 ml of blood before treatment (day −9), and none were detected after therapy (day +190). - There was no definitive evidence of recurrence at 17 months. The most recent imaging, at day +526, showed grossly stable postsurgical changes and no features to suggest recurrent disease, against a median overall survival of 14.1 months reported for MGMT-unmethylated glioblastoma on standard care. ## The AccuCyte–CyteFinder workflow in the methods “A total of 7.5 ml whole-blood samples were processed using the AccuCyte-CyteFinder platform (RareCyte)” — Long et al., Nature Medicine (2025), Methods, “CTC analysis” Disclosure: RareCyte is named in the competing-interests statement of the publication cited above. ## Why it matters for The AccuCyte–CyteFinder workflow users If you track circulating tumor cells across a treatment course, look at what this case asked of the counting step. Glioblastoma tumor cells are rare in blood and lack the epithelial markers most enrichment methods select on, so here they were called on glial identity instead — positive for the nuclear dye DAPI, the astrocytic marker GFAP and EGFR, and negative for the leukocyte markers CD45 and CD66b. That readout only holds if the candidate cells are still on the slide to be scored. The AccuCyte–CyteFinder workflow isolates every nucleated cell from 7.5 ml of whole blood by density rather than selecting for a surface antigen first, then images the deposited population on the CyteFinder HT. That is what let this study count 16 tumor cells before treatment and confirm none afterward in the same patient. Treat the number as a research enumeration, not a clinical test — what the workflow supplies is a reliable count of rare cells you would otherwise lose to up-front selection. When the endpoint is a serial cell count, keeping every candidate in view is the property that carries it. [Back to all resources](/#library) ## Related resources [Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) CyteFinder Journal of Clinical Oncology 2026 ### Clinical validation of circulating tumor cell synaptophysin and androgen receptor expression in metastatic prostate cancer phenotypes. [View Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) [Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) CyteFinder 2026 ### Dr. Pashtoon Kasi on the impact of circulating tumor cells on clinical research [Watch Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) CyteFinder Nature Communications 2026 ### Extracellular matrix mediates circulating tumor cell clustering in triple-negative breast cancer metastasis [View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) [Publication](https://doi.org/10.1016/j.ejso.2025.111357) CyteFinder European Journal of Surgical Oncology 2026 ### Circulating tumor cells predict relapse in head and neck mucosal squamous cell carcinoma [View Publication](https://doi.org/10.1016/j.ejso.2025.111357) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) CyteFinder Cancer Research Communications 2026 ### Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer [View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) [Publication](https://doi.org/10.3390/cancers17162717) CyteFinder Cancers 2025 ### Comprehensive Longitudinal Linear Mixed Modelling of CTCs Illuminates the Role of Trop2, EpCAM, and CD45 in CTC Clustering and Metastasis [View Publication](https://doi.org/10.3390/cancers17162717) [Publication](https://doi.org/10.1080/07366205.2025.2534299) CyteFinder BioTechniques 2025 ### A novel device for buffy coat collection [View Publication](https://doi.org/10.1080/07366205.2025.2534299) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) CyteFinder 2025 ### Development of a CTC Based Assay to Characterize MAOA Expression in Metastatic Prostate Cancer [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/43fb6d4a8510166e936d250b3bf172e2f669bfa3.pdf) CyteFinder 2025 ### Quantitative analysis of HER2, HER3, and γH2AX expression on circulating tumor cells for pharmacodynamic measurement in clinical trials [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/43fb6d4a8510166e936d250b3bf172e2f669bfa3.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11985722/) CyteFinder Cellular and Molecular Life Sciences 2025 ### Portal venous circulating tumor cells as a biomarker for relapse prediction in resected pancreatic cancer [View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11985722/) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/f6e029d0a3ad855ff644046c0b1c1c20cf771df2.pdf) CyteFinder Orion 2024 ### Next Gen Liquid Biopsy: Comprehensive Analysis from a Single Tube of Blood [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/f6e029d0a3ad855ff644046c0b1c1c20cf771df2.pdf) [Webinar](https://www.youtube.com/watch?v=vJ3YH4z1YKI) CyteFinder 2024 ### New Discoveries in HER2 Detection: A Novel Method of Multimodal Detection of HER2 from a Single Tube of Blood [Watch Webinar](https://www.youtube.com/watch?v=vJ3YH4z1YKI)